In Vitro Response of Immunoregulatory Cytokine Expression in Human Monocytic Cells to Human Parvovirus B19 Capsid

DOI Web Site Web Site 参考文献35件
  • Fujita Tetsuhiro
    Department of Pharmacotherapeutics, Showa Pharmaceutical University
  • Ikejima Hideaki
    Department of Pharmacotherapeutics, Showa Pharmaceutical University
  • Yamagata Nanako
    Department of Pharmacotherapeutics, Showa Pharmaceutical University
  • Kudo Yuko
    Department of Pharmacotherapeutics, Showa Pharmaceutical University
  • Hoshi Keiko
    Department of Pharmacotherapeutics, Showa Pharmaceutical University

この論文をさがす

抄録

Human parvovirus B19 is a clinically important pathogen in both children and adults. In adults, it frequently causes acute and chronic arthritis, which may be related to persistent infection. The effect of the capsid of human parvovirus B19 on monocytes, which are thought to be responsible for the first line of defense against parvoviral infection, is not well understood. In this study, we investigated changes in mRNA expression levels of several immunoregulatory cytokines in monocytic cells after treatment with the B19 capsid. When human monocytic cell line THP-1 cells were treated with the B19 capsid, the expression of tumor necrosis factor alpha (TNF-α) mRNA was suppressed independently of transforming growth factor beta (TGF-β) mRNA. In contrast, the level of mRNA for interleukin-1 alpha (IL-1α) remained unchanged, and that for interleukin-1 beta (IL-1β) was slightly increased after the capsid treatment. Flow cytometry demonstrated that THP-1 cells treated with B19 capsid showed no differences in surface expression of CD11a, CD16 and CD33, as compared with control cells. These findings that B19 capsid antigen did not promote positive responses for production of TNF-α and IL-1α may provide insight into the mechanisms of persistent infection of human parvovirus B19 and the systemic viral spread via bloodstream.

収録刊行物

参考文献 (35)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ